Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

The Innovation

Zhi Peng¹  Zhenghang Wang¹  Lin Shen¹  Xi Jiao¹  Chang Liu²  Jian Li²  Zhihao Lu²  Yakun Wang² 

[1] Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, China;;Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital &

关键词: gastrointestinal cancer;    immune checkpoint blockade;    biomarkers;    precision immunotherapy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.

【 授权许可】

Unknown